Product nameAnti-CD45 antibody [HI30]
See all CD45 primary antibodies
DescriptionMouse monoclonal [HI30] to CD45
Tested applicationsSuitable for: WB, IP, IHC-Fr, Functional Studies, ICC, Flow Cyt, IHC-P, Blockingmore details
Species reactivityReacts with: Human, Non human primates
Immunogen information is proprietary
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at +4°C. Avoid freeze / thaw cycle. Store undiluted.
Storage bufferpH: 7.2
Preservative: 0.09% Sodium azide
Constituents: 0.87% Sodium chloride, 0.14% Monobasic dihydrogen sodium phosphate
Concentration information loading...
Purification notesab123522 was determined to be >90% pure by SDS-PAGE.
- Anti-CD45 antibody [HI30] (PE/Cy7 ®) (ab155340)
- Anti-CD45 antibody [HI30], prediluted (PE/Cy5®) (ab155385)
- Anti-CD45 antibody [HI30] (PE/Cy5.5 ®) (ab167004)
- Anti-CD45 antibody [HI30] (Allophycocyanin) (ab210270)
- Anti-CD45 antibody [HI30] (FITC) (ab210272)
- Anti-CD45 antibody [HI30] (Phycoerythrin) (ab210273)
- Anti-CD45 antibody [HI30] (redFluor™ 710) (ab242257)
- Anti-CD45 antibody [HI30] (ab253085)
Our Abpromise guarantee covers the use of ab123522 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent concentration. Predicted molecular weight: 147 kDa.|
|IP||Use at an assay dependent concentration.|
|IHC-Fr||Use at an assay dependent concentration.|
|Functional Studies||Use at an assay dependent concentration.|
|ICC||Use at an assay dependent concentration.|
|Flow Cyt||Use at an assay dependent concentration.
ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
|IHC-P||Use at an assay dependent concentration.|
|Blocking||Use at an assay dependent concentration.|
FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains.
DomainThe first PTPase domain interacts with SKAP1.
modificationsHeavily N- and O-glycosylated.
Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
- Information by UniProt
- B220 antibody
- CD 45 antibody
- CD45 antibody
Human peripheral blood lymphocytes stained with ab123522 (red line). Human whole blood was processed using a modified protocol based on Chow et al, 2005 (PMID: 16080188). In brief, human whole blood was fixed in 4% formaldehyde (methanol-free) for 10 min at 22°C. Red blood cells were then lyzed by the addition of Triton X-100 (final concentration - 0.1%) for 15 min at 37°C. For experimentation, cells were treated with 50% methanol (-20°C) for 15 min at 4°C. Cells were then incubated with the antibody (ab123522, 0.1μg/1x106 cells) for 30 min at 4°C. The secondary antibody used was Alexa Fluor® 488 goat anti-mouse IgG (H&L) (ab150113) at 1/2000 dilution for 30 min at 4°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 0.1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >30,000 total events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter. Gating strategy - peripheral blood lymphocytes.
ab123522 has not yet been referenced specifically in any publications.